VIRUS PLUS (influenzinum- 2016-2017, adenoviren nosode, herpes simplex 1 nosode, herpes simplex 2 nosode, cytomegalovirus nosode United States - English - NLM (National Library of Medicine)

virus plus (influenzinum- 2016-2017, adenoviren nosode, herpes simplex 1 nosode, herpes simplex 2 nosode, cytomegalovirus nosode

deseret biologicals, inc. - influenza a virus a/california/7/2009 x-181 (h1n1) hemagglutinin antigen (propiolactone inactivated) (unii: mhg4xw7big) (influenza a virus a/california/7/2009 x-181 (h1n1) hemagglutinin antigen (propiolactone inactivated) - unii:mhg4xw7big), influenza a virus a/hong kong/4801/2014 x-263b (h3n2) hemagglutinin antigen (propiolactone inactivated) (unii: c2c4da5k06) (influenza a virus a/hong kong/4801/2014 x-263b (h3n2) hemagglutinin antigen (propiolactone inactivated) - unii:c2c4da5k06), influenza b virus b/ - influenza a virus a/california/7/2009 x-181 (h1n1) hemagglutinin antigen (propiolactone inactivated) 12 [hp_x] in 1 ml - for temporary relief of symptoms related to general viral infection (such as influenza, epstein-barr virus [ebv], cytomegalovirus [cmv], hepatitis, herpes, or adenovirus) including fever, fatigue, muscle aches and pain, rash, cold sores, headache and confusion.** **these statements are based upon traditional homeopathic principles. they have not been reviewed by the food and drug administration. for temporary relief of symptoms related to general viral infection (such as influenza, epstein-barr virus [ebv], cytomegalovirus [cmv], hepatitis, herpes, or adenovirus) including fever, fatigue, muscle aches and pain, rash, cold sores, headache and confusion.** **these statements are based upon traditional homeopathic principles. they have not been reviewed by the food and drug administration.

VIRUS PLUS (influenzinum- 2015-2016, adenoviren nosode, herpes simplex 1, herpes simplex 2, cytomegalovirus nosode, epstein-barr United States - English - NLM (National Library of Medicine)

virus plus (influenzinum- 2015-2016, adenoviren nosode, herpes simplex 1, herpes simplex 2, cytomegalovirus nosode, epstein-barr

deseret biologicals, inc. - influenza a virus a/brisbane/10/2010 (h1n1) hemagglutinin antigen (mdck cell derived, propiolactone inactivated) (unii: kfl1w6w9jb) (influenza a virus a/brisbane/10/2010 (h1n1) hemagglutinin antigen (mdck cell derived, propiolactone inactivated) - unii:kfl1w6w9jb), influenza a virus a/brisbane/10/2010 (h1n1) neuraminidase antigen (mdck cell derived, propiolactone inactivated) (unii: 80t3qs071u) (influenza a virus a/brisbane/10/2010 (h1n1) neuraminidase antigen (mdck cell derived, propiolactone inactivated - influenza a virus a/brisbane/10/2010 (h1n1) hemagglutinin antigen (mdck cell derived, propiolactone inactivated) 12 [hp_x] in 1 ml - for temporary relief of symptoms related to general viral infection (such as influenza, epstein-barr virus [ebv], cytomegalovirus [cmv], hepatitis, herpes, or adenovirus) including fever, fatigue, muscle aches and pain, rash, cold sores, headache and confusion.** **these statements are based upon traditional homeopathic principles. they have not been reviewed by the food and drug administration. for temporary relief of symptoms related to general viral infection (such as influenza, epstein-barr virus [ebv], cytomegalovirus [cmv], hepatitis, herpes, or adenovirus) including fever, fatigue, muscle aches and pain, rash, cold sores, headache and confusion.** **these statements are based upon traditional homeopathic principles. they have not been reviewed by the food and drug administration.

VIRUS PLUS (influenzinum- 2015-2016, adenoviren nosode, herpes simplex 1 nosode, herpes simplex 2 nosode, cytomegalovirus nosode United States - English - NLM (National Library of Medicine)

virus plus (influenzinum- 2015-2016, adenoviren nosode, herpes simplex 1 nosode, herpes simplex 2 nosode, cytomegalovirus nosode

deseret biologicals, inc. - influenza a virus a/brisbane/10/2010 (h1n1) hemagglutinin antigen (mdck cell derived, propiolactone inactivated) (unii: kfl1w6w9jb) (influenza a virus a/brisbane/10/2010 (h1n1) hemagglutinin antigen (mdck cell derived, propiolactone inactivated) - unii:kfl1w6w9jb), influenza a virus a/brisbane/10/2010 (h1n1) neuraminidase antigen (mdck cell derived, propiolactone inactivated) (unii: 80t3qs071u) (influenza a virus a/brisbane/10/2010 (h1n1) neuraminidase antigen (mdck cell derived, propiolactone inactivated - influenza a virus a/brisbane/10/2010 (h1n1) hemagglutinin antigen (mdck cell derived, propiolactone inactivated) 12 [hp_x] in 1 ml - for temporary relief of symptoms related to general viral infection (such as influenza, epstein-barr virus [ebv], cytomegalovirus [cmv], hepatitis, herpes, or adenovirus) including fever, fatigue, muscle aches and pain, rash, cold sores, swollen glands, headache and confusion.** **these statements are based upon traditional homeopathic principles. they have not been reviewed by the food and drug administration. for temporary relief of symptoms related to general viral infection (such as influenza, epstein-barr virus [ebv], cytomegalovirus [cmv], hepatitis, herpes, or adenovirus) including fever, fatigue, muscle aches and pain, rash, cold sores, swollen glands, headache and confusion.** **these statements are based upon traditional homeopathic principles. they have not been reviewed by the food and drug administration.

Infanrix Hexa powder and suspension for suspension for injection Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

infanrix hexa powder and suspension for suspension for injection

glaxosmithkline biologicals s.a. - diphtheria toxoid, tetanus toxoid, pertussis toxoid, filamentous haemagglutinin, pertactin, hepatitis b surface antigen, inactivated poliovirus type 1, inactivated poliovirus type 2, inactivated poliovirus type 3, haemophilus influenzae type b polysaccharide (conjugated to tetanus toxoid) - powder and suspension for suspension for injection - not less than 30iu/dose+ not less than 40iu/dose+ 25mcg/dose+ 25mcg/dose+ 8mcg/dose+ 10mcg/dose+ 40d-antigen unit/dose+ 8d-antig

FLUAD inactivated influenza vaccine (surface antigen) suspension for injection, adjuvanted, 0.5 mL syringe 2019 Australia - English - Department of Health (Therapeutic Goods Administration)

fluad inactivated influenza vaccine (surface antigen) suspension for injection, adjuvanted, 0.5 ml syringe 2019

seqirus pty ltd - influenza virus haemagglutinin, quantity: 30 microgram/ml - injection, suspension - excipient ingredients: sodium chloride; potassium chloride; monobasic potassium phosphate; dibasic sodium phosphate dihydrate; magnesium chloride hexahydrate; calcium chloride dihydrate; squalene; polysorbate 80; sorbitan trioleate; sodium citrate dihydrate; citric acid monohydrate; water for injections - active immunisation against influenza in the elderly (65 years of age and older), especially for those with an increased risk of associated complications (i.e. patients affected by underlying chronic diseases including diabetes, cardiovascular and respiratory diseases).

FLUAD inactivated influenza vaccine (surface antigen) suspension for injection, adjuvanted, 0.5 mL syringe 2019 Australia - English - Department of Health (Therapeutic Goods Administration)

fluad inactivated influenza vaccine (surface antigen) suspension for injection, adjuvanted, 0.5 ml syringe 2019

seqirus pty ltd - influenza virus haemagglutinin, quantity: 30 microgram/ml - injection, suspension - excipient ingredients: sodium chloride; potassium chloride; monobasic potassium phosphate; dibasic sodium phosphate dihydrate; magnesium chloride hexahydrate; calcium chloride dihydrate; squalene; polysorbate 80; sorbitan trioleate; sodium citrate dihydrate; citric acid monohydrate; water for injections - active immunisation against influenza in the elderly (65 years of age and older), especially for those with an increased risk of associated complications (i.e. patients affected by underlying chronic diseases including diabetes, cardiovascular and respiratory diseases).

FLUAD QUAD inactivated quadrivalent influenza vaccine (surface antigen) adjuvanted suspension for injection 60 mcg HA/ 0.5 mL PFS with attached needle, 2024 Season Australia - English - Department of Health (Therapeutic Goods Administration)

fluad quad inactivated quadrivalent influenza vaccine (surface antigen) adjuvanted suspension for injection 60 mcg ha/ 0.5 ml pfs with attached needle, 2024 season

seqirus pty ltd - influenza virus haemagglutinin, quantity: 15 microgram - injection, suspension - excipient ingredients: monobasic potassium phosphate; magnesium chloride hexahydrate; sorbitan trioleate; squalene; sodium citrate dihydrate; citric acid monohydrate; calcium chloride dihydrate; potassium chloride; water for injections; sodium chloride; dibasic sodium phosphate dihydrate; polysorbate 80 - active immunisation against influenza in persons 65 years of age and older.